95 related articles for article (PubMed ID: 32663328)
1. Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver.
El Dika I; Bowman AS; Berger MF; Capanu M; Chou JF; Benayed R; Zehir A; Shia J; O'Reilly EM; Klimstra DS; Solit DB; Abou-Alfa GK
Cancer; 2020 Sep; 126(18):4126-4135. PubMed ID: 32663328
[TBL] [Abstract][Full Text] [Related]
2. Unique genomic profile of fibrolamellar hepatocellular carcinoma.
Cornella H; Alsinet C; Sayols S; Zhang Z; Hao K; Cabellos L; Hoshida Y; Villanueva A; Thung S; Ward SC; Rodriguez-Carunchio L; Vila-Casadesús M; Imbeaud S; Lachenmayer A; Quaglia A; Nagorney DM; Minguez B; Carrilho F; Roberts LR; Waxman S; Mazzaferro V; Schwartz M; Esteller M; Heaton ND; Zucman-Rossi J; Llovet JM
Gastroenterology; 2015 Apr; 148(4):806-18.e10. PubMed ID: 25557953
[TBL] [Abstract][Full Text] [Related]
3. GalNAc-conjugated siRNA targeting the DNAJB1-PRKACA fusion junction in fibrolamellar hepatocellular carcinoma.
Neumayer C; Ng D; Requena D; Jiang CS; Qureshi A; Vaughan R; Prakash TP; Revenko A; Simon SM
Mol Ther; 2024 Jan; 32(1):140-151. PubMed ID: 37980543
[TBL] [Abstract][Full Text] [Related]
4. DNAJB1-PRKACA fusion protein-regulated LINC00473 promotes tumor growth and alters mitochondrial fitness in fibrolamellar carcinoma.
Ma RK; Tsai PY; Farghli AR; Shumway A; Kanke M; Gordan JD; Gujral TS; Vakili K; Nukaya M; Noetzli L; Ronnekleiv-Kelly S; Broom W; Barrow J; Sethupathy P
PLoS Genet; 2024 Mar; 20(3):e1011216. PubMed ID: 38512964
[TBL] [Abstract][Full Text] [Related]
5. FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion.
Hackenbruch C; Bauer J; Heitmann JS; Maringer Y; Nelde A; Denk M; Zieschang L; Kammer C; Federmann B; Jung S; Martus P; Malek NP; Nikolaou K; Salih HR; Bitzer M; Walz JS
Front Oncol; 2024; 14():1367450. PubMed ID: 38606105
[TBL] [Abstract][Full Text] [Related]
6. DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma.
Kirk AM; Crawford JC; Chou CH; Guy C; Pandey K; Kozlik T; Shah RK; Chung S; Nguyen P; Zhang X; Wang J; Bell M; Mettelman RC; Allen EK; Pogorelyy MV; Kim H; Minervina AA; Awad W; Bajracharya R; White T; Long D; Gordon B; Morrison M; Glazer ES; Murphy AJ; Jiang Y; Fitzpatrick EA; Yarchoan M; Sethupathy P; Croft NP; Purcell AW; Federico SM; Stewart E; Gottschalk S; Zamora AE; DeRenzo C; Strome SE; Thomas PG
Cell Rep Med; 2024 Mar; 5(3):101469. PubMed ID: 38508137
[TBL] [Abstract][Full Text] [Related]
7. Fibrolamellar Carcinoma: Recent Advances and Unresolved Questions on the Molecular Mechanisms.
Lalazar G; Simon SM
Semin Liver Dis; 2018 Feb; 38(1):51-59. PubMed ID: 29471565
[TBL] [Abstract][Full Text] [Related]
8. Reversing immunosuppression in the tumor microenvironment of fibrolamellar carcinoma via PD-1 and IL-10 blockade.
Daniel SK; Sullivan KM; Dickerson LK; van den Bijgaart RJE; Utria AF; Labadie KP; Kenerson HL; Jiang X; Smythe KS; Campbell JS; Pierce RH; Kim TS; Riehle KJ; Yeung RS; Carter JA; Barry KC; Pillarisetty VG
Sci Rep; 2024 Mar; 14(1):5109. PubMed ID: 38429349
[TBL] [Abstract][Full Text] [Related]
9. Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient-Derived Xenografts and Direct-from-Patient Screening.
Lalazar G; Requena D; Ramos-Espiritu L; Ng D; Bhola PD; de Jong YP; Wang R; Narayan NJC; Shebl B; Levin S; Michailidis E; Kabbani M; Vercauteren KOA; Hurley AM; Farber BA; Hammond WJ; Saltsman JA; Weinberg EM; Glickman JF; Lyons BA; Ellison J; Schadde E; Hertl M; Leiting JL; Truty MJ; Smoot RL; Tierney F; Kato T; Wendel HG; LaQuaglia MP; Rice CM; Letai A; Coffino P; Torbenson MS; Ortiz MV; Simon SM
Cancer Discov; 2021 Oct; 11(10):2544-2563. PubMed ID: 34127480
[TBL] [Abstract][Full Text] [Related]
10. Recruitment of BAG2 to DNAJ-PKAc scaffolds promotes cell survival and resistance to drug-induced apoptosis in fibrolamellar carcinoma.
Lauer SM; Omar MH; Golkowski MG; Kenerson HL; Lee KS; Pascual BC; Lim HC; Forbush K; Smith FD; Gordan JD; Ong SE; Yeung RS; Scott JD
Cell Rep; 2024 Feb; 43(2):113678. PubMed ID: 38236773
[TBL] [Abstract][Full Text] [Related]
11. Mesonephric and mesonephric-like adenocarcinomas of gynecologic origin: A single-center experience with molecular characterization, treatment, and oncologic outcomes.
Praiss AM; White C; Iasonos A; Selenica P; Zivanovic O; Chi DS; Abu-Rustum NR; Weigelt B; Aghajanian C; Girshman J; Park KJ; Grisham RN
Gynecol Oncol; 2024 Mar; 182():32-38. PubMed ID: 38246044
[TBL] [Abstract][Full Text] [Related]
12. Molecular profiling in the management of hepatocellular carcinoma.
Soliman N; Saharia A; Abdelrahim M; Connor AA
Curr Opin Organ Transplant; 2024 Feb; 29(1):10-22. PubMed ID: 38038621
[TBL] [Abstract][Full Text] [Related]
13. Phase Separation of a PKA Regulatory Subunit Controls cAMP Compartmentation and Oncogenic Signaling.
Zhang JZ; Lu TW; Stolerman LM; Tenner B; Yang JR; Zhang JF; Falcke M; Rangamani P; Taylor SS; Mehta S; Zhang J
Cell; 2020 Sep; 182(6):1531-1544.e15. PubMed ID: 32846158
[TBL] [Abstract][Full Text] [Related]
14. A Prognostic Prediction Model Developed Based on Four CpG Sites and Weighted Correlation Network Analysis Identified
Kong L; Liu P; Fei X; Wu T; Wang Z; Zhang B; Li J; Tan X
Front Oncol; 2020; 10():1716. PubMed ID: 32984053
[TBL] [Abstract][Full Text] [Related]
15. Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer.
Keenan TE; Li T; Vallius T; Guerriero JL; Tayob N; Kochupurakkal B; Davis J; Pastorello R; Tahara RK; Anderson L; Conway J; He MX; Shannon E; Godin RE; Sorger PK; D'Andrea A; Overmoyer B; Winer EP; Mittendorf EA; Van Allen EM; Shapiro GI; Tolaney SM
Clin Cancer Res; 2021 Feb; 27(4):983-991. PubMed ID: 33257427
[TBL] [Abstract][Full Text] [Related]
16. Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines.
Lacouture ME; Sibaud V; Anadkat MJ; Kaffenberger B; Leventhal J; Guindon K; Abou-Alfa G
Oncologist; 2021 Feb; 26(2):e316-e326. PubMed ID: 33021006
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.
Yau T; Kang YK; Kim TY; El-Khoueiry AB; Santoro A; Sangro B; Melero I; Kudo M; Hou MM; Matilla A; Tovoli F; Knox JJ; Ruth He A; El-Rayes BF; Acosta-Rivera M; Lim HY; Neely J; Shen Y; Wisniewski T; Anderson J; Hsu C
JAMA Oncol; 2020 Nov; 6(11):e204564. PubMed ID: 33001135
[TBL] [Abstract][Full Text] [Related]
18. Genomic Characterization of
Mondaca S; Razavi P; Xu C; Offin M; Myers M; Scaltriti M; Hechtman JF; Bradley M; O'Reilly EM; Berger MF; Solit DB; Li BT; Abou-Alfa GK
JCO Precis Oncol; 2019; 3():. PubMed ID: 32923849
[TBL] [Abstract][Full Text] [Related]
19. Fibrolamellar carcinoma: Challenging the challenge.
Lamarca A; Frizziero M; Fulton A; McNamara MG; Filobbos R; Hubner RA; Wardell S; Valle JW
Eur J Cancer; 2020 Sep; 137():144-147. PubMed ID: 32768872
[TBL] [Abstract][Full Text] [Related]
20. Fibrolamellar hepatocellular carcinoma that was successfully treated with surgical resection: a case report.
Na SK
J Liver Cancer; 2022 Sep; 22(2):178-182. PubMed ID: 37383417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
